| Revenue | $16.99B | ▲ +10.2% — 3rd straight Q2 of growth |
| Net Income | $3.60B | ▲ +288.0% |
| EPS | $2.04 | ▲ +292.3% |
| Profitability & Cash Flow | ||
| Pro Op Cash Flow · Net Margin · Gross Margin · Op Margin | ||
| Capital Returns | ||
| Pro Buybacks · Dividends · Stock-based comp · Share change | ||
| Balance Sheet | ||
| Pro Cash & equivalents · Long-term debt | ||
Filing Events
Abbvie Inc. (ABBV) filed its latest earnings report on October 6, 2026; detailed figures from it will appear here once available. The most recent complete reporting period is Q2 2026. Revenue was $16.99B, up 10.2% year-over-year — its 3rd straight Q2 of growth. Net income was $3.60B (up 288.0%) and EPS was $2.04 (up 292.3%). ABBV's next report is expected around January 5, 2027 (estimated from its filing history). Source: SEC filing.
Abbvie Inc. is expected to report around January 5, 2027, estimated from its filing history (the exact date is announced by the company). The Earnings Watcher sends a free email alert the day it files.
Abbvie Inc. (ABBV) filed its latest earnings report on October 6, 2026; detailed figures from it will appear here once available. The most recent complete reporting period is Q2 2026. Revenue was $16.99B, up 10.2% year-over-year — its 3rd straight Q2 of growth. Net income was $3.60B (up 288.0%) and EPS was $2.04 (up 292.3%).
The full earnings release, as filed with the SEC on October 6, 2026, is available on this page below the summary.
| (in millions, except per share data) | Quarter Ended September 30, 2026 | Full-Year Ended December 31, 2026 | |||||||||||||||||||||||||||||||||
| Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | ||||||||||||||||||||||||||||||||
| Low | High | Low | High | ||||||||||||||||||||||||||||||||
Previously announced guidance excluding Q3 2026 acquired IPR&D and milestones expense | $ | — | $ | 3.84 | $ | 3.88 | $ | 1,035 | $ | 13.87 | $ | 14.07 | |||||||||||||||||||||||
| Q3 2026 acquired IPR&D and milestones expense | 216 | (0.11) | (0.11) | 216 | (0.11) | (0.11) | |||||||||||||||||||||||||||||
Guidance including Q3 2026 acquired IPR&D and milestones expensea | $ | 216 | $ | 3.73 | $ | 3.77 | $ | 1,251 | $ | 13.76 | $ | 13.96 | |||||||||||||||||||||||